Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Bristol gained Cobenfy through its $14B acquisition of Karuna Therapeutics that closed in March. AbbVie, however, can still make the most out of its Cerevel purchase. Emraclidine is also in phase ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Cobenfy introduces a fundamentally new approach ... Bristol Myers acquired KarXT as part of its acquisition of Karuna Therapeutics Inc. earlier this year. Related: Bristol Myers's stock pops ...

Bristol Myers got the medicine, now sold as Cobenfy, through a $14 billion deal for Karuna Therapeutics that closed in March. AbbVie’s acquisition “just went up in flames,” according to ...